Home » Progenics Extends Agreement With Pfizer for Relistor Commercialization
Progenics Extends Agreement With Pfizer for Relistor Commercialization
Progenics Pharmaceuticals, Inc. Monday announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s commercialization of Relistor (methylnaltrexone bromide) Subcutaneous Injection in the United States through at least December 31, 2010.
Earth Times
Earth Times
Upcoming Events
-
07May
-
14May
-
30May